|
Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA. |
|
|
Honoraria - Roche; Takeda |
Consulting or Advisory Role - ADC Therapeutics; Amgen; Bayer; Bristol-Myers Squibb; Celgene; Janssen; Kite, a Gilead company; Morphosys; MSD; Mundipharma; Novartis; Roche; Sandoz; Seagen; Spectrum Pharmaceuticals |
Research Funding - Amgen; Roche; Spectrum Pharmaceuticals |
Travel, Accommodations, Expenses - Amgen; Janssen; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Roche |
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Gilead Sciences; Sandoz |
Consulting or Advisory Role - Celgene; Roche |
Travel, Accommodations, Expenses - Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Sanofi |
|
|
Consulting or Advisory Role - Novartis; Teva |
Travel, Accommodations, Expenses - Novartis; Teva |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Gilead Sciences; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Roche |